In a randomized, placebo-controlled trial involving patients 12 to 65 years of age with eosinophilic esophagitis, benralizumab reduced esophageal eosinophil counts but did not reduce dysphagia symptoms.
The New England Journal of Medicine: Search Results in Allergy/Immunology
